Compared with the single agent treatment groups with either dox or ixazomib, the combination group showed stronger PARP and Caspase-3 cleavages in all six of the cell lines tested (Fig. 5a–f), suggesting that ixazomib enhances dox-induced apoptosis in NB cells. Here, CASP3 is linked to neuroblastoma.